Gracell Biotechnologies Investor Relations Material
Latest events
Q3 2023
Gracell Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gracell Biotechnologies Inc
Access all reports
Gracell Biotechnologies Inc. (GRCL) is a clinical-stage biopharmaceutical company primarily focused on discovering and developing innovative cell therapies for cancer treatment. The company leverages its proprietary FasTCAR and TruUCAR technology platforms, along with its SMART CART™ technology module, to develop therapies designed to offer fast, deep, and durable responses for patients suffering from cancer and autoimmune diseases. Gracell Biotechnologies is headquartered in Suzhou, China, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GRCL
Country
🇺🇸 United States